Recursion Pharmaceuticals
RXRX
RXRX
146 hedge funds and large institutions have $1.21B invested in Recursion Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 63 increasing their positions, 29 reducing their positions, and 11 closing their positions.
Holders
146
Holders Change
+13
Holders Change %
+9.77%
% of All Funds
2.52%
Holding in Top 10
8
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.14%
New
24
Increased
63
Reduced
29
Closed
11
Calls
$1.1M
Puts
$455K
Net Calls
+$647K
Net Calls Change
+$736K
Top Buyers
| 1 |
1
State Street
Boston,
Massachusetts
|
$48.5M |
| 2 |
2
BlackRock
New York
|
$104M |
| 3 |
3
Fidelity Investments
Boston,
Massachusetts
|
$45.2M |
| 4 |
4
Vanguard Group
Malvern,
Pennsylvania
|
$89.2M |
| 5 |
DFO
5
Duquesne Family Office
New York
|
$14.7M |
